Toll-like-receptor-agonists - Pipeline Insight, 2021
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Toll-like-receptor-agonists - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Toll-like-receptor-agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Toll-like-receptor-agonists: Overview
TLR agonists play a fundamental role in activating innate and adaptive immune responses. The engagement of specific TLRs on cancer cells can impact tumor growth by various mechanisms, including inducing apoptosis and potentiating the effects of chemotherapy. Various TLRs have been reported to be expressed on a multitude of cancer types. TLR3 and TLR5 show the most promise for eliciting direct antitumor effects, whereas TLR4, -7, -8, and -9 display primarily protumor properties when stimulated on tumor cells. The use of multi-TLR agonists to induce potent antitumor responses remains a promising topic of research despite limited clinical evidence supporting the use of systemic TLR agonists as monotherapies.
'Toll-like-receptor-agonists - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Toll-like-receptor-agonists pipeline landscape is provided which includes the disease overview and Toll-like-receptor-agonists treatment guidelines. The assessment part of the report embraces, in depth Toll-like-receptor-agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Toll-like-receptor-agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Toll-like-receptor-agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Toll-like-receptor-agonists Emerging Drugs
Further product details are provided in the report.
Toll-like-receptor-agonists: Therapeutic Assessment
This segment of the report provides insights about the different Toll-like-receptor-agonists drugs segregated based on following parameters that define the scope of the report, such as:
Toll-like-receptor-agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Toll-like-receptor-agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-like-receptor-agonists drugs.
Toll-like-receptor-agonists Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Toll-like-receptor-agonists - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Toll-like-receptor-agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Toll-like-receptor-agonists: Overview
TLR agonists play a fundamental role in activating innate and adaptive immune responses. The engagement of specific TLRs on cancer cells can impact tumor growth by various mechanisms, including inducing apoptosis and potentiating the effects of chemotherapy. Various TLRs have been reported to be expressed on a multitude of cancer types. TLR3 and TLR5 show the most promise for eliciting direct antitumor effects, whereas TLR4, -7, -8, and -9 display primarily protumor properties when stimulated on tumor cells. The use of multi-TLR agonists to induce potent antitumor responses remains a promising topic of research despite limited clinical evidence supporting the use of systemic TLR agonists as monotherapies.
'Toll-like-receptor-agonists - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Toll-like-receptor-agonists pipeline landscape is provided which includes the disease overview and Toll-like-receptor-agonists treatment guidelines. The assessment part of the report embraces, in depth Toll-like-receptor-agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Toll-like-receptor-agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Toll-like-receptor-agonists R&D. The therapies under development are focused on novel approaches to treat/improve Toll-like-receptor-agonists.
This segment of the Toll-like-receptor-agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Toll-like-receptor-agonists Emerging Drugs
- Cobitolimod: InDex Pharmaceuticals
- Tilsotolimod: Idera Pharmaceuticals
Further product details are provided in the report.
Toll-like-receptor-agonists: Therapeutic Assessment
This segment of the report provides insights about the different Toll-like-receptor-agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Toll-like-receptor-agonists
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Toll-like-receptor-agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Toll-like-receptor-agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-like-receptor-agonists drugs.
Toll-like-receptor-agonists Report Insights
- Toll-like-receptor-agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Toll-like-receptor-agonists drugs?
- How many Toll-like-receptor-agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Toll-like-receptor-agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Toll-like-receptor-agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Toll-like-receptor-agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- InDex Pharmaceuticals
- Mologen
- Idera Pharmaceuticals
- Exicure
- Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals
- Cobitolimod
- Lefitolimod
- Tilsotolimod
- Cavrotolimod
- BDB-001
- BDB-030
- BDB-018
Introduction
Executive Summary
Toll-like-receptor-agonists: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Cobitolimod: InDex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Cavrotolimod: Exicure
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early stage products (Phase I)
Comparative Analysis
BDB-018: Seven and Eight Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
Comparative Analysis
BDB-030: Seven and Eight Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Toll-like-receptor-agonists Key Companies
Toll-like-receptor-agonists Key Products
Toll-like-receptor-agonists- Unmet Needs
Toll-like-receptor-agonists- Market Drivers and Barriers
Appendix
Executive Summary
Toll-like-receptor-agonists: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Cobitolimod: InDex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
Cavrotolimod: Exicure
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early stage products (Phase I)
Comparative Analysis
BDB-018: Seven and Eight Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
Comparative Analysis
BDB-030: Seven and Eight Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Toll-like-receptor-agonists Key Companies
Toll-like-receptor-agonists Key Products
Toll-like-receptor-agonists- Unmet Needs
Toll-like-receptor-agonists- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Toll-like-receptor-agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Toll-like-receptor-agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Toll-like-receptor-agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Toll-like-receptor-agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products